The Health Sciences Authority (HSA) of Singapore and China’s National Medical Products Administration have expanded their regulatory cooperation to encompass cell, tissue, and gene products, alongside existing collaborations on drugs and medical devices. This enhancement, formalized through a memorandum of understanding (MOU) signed on May 11, 2026, aims to facilitate faster access to innovative health products while ensuring safety and quality standards. The agreement also promotes shared efforts in regulatory information exchange, standards, and combating counterfeit health products. This renewed partnership builds on over 20 years of collaboration and is expected to streamline the development and market access processes for new medical technologies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://healthcareasiamagazine.com/news/singapore-and-china-broaden-drug-oversight-deal-cover-gene-therapies
